TABLE 1.
Summary of the antibiotic resistance determined by disk diffusion testing and sequencing
| Antibiotica | Disk diffusion testing results |
Sequencing results |
||||
|---|---|---|---|---|---|---|
| Zone of inhibition (mm) | Sensitivity range (μg/ml) | Susceptibilityb | Gene(s) associated | Mutation associated | Location | |
| Aminoglycosides | ||||||
| GEN | 12 | <12 to >15 | R | aac(6′)-Ie-aph(2ʺ)-Ia, aph(3′)-IIIa, aad(6) | Genome | |
| TOB | 17 | <17 to >19 | R | |||
| AMK | 25 | <14 to >17 | S | |||
| Fluoroquinolones | ||||||
| CIP | 9 | <20 to >22 | R | Point mutations in gyrA (positions 12, 251, 2023, and 2140) | Genome | |
| MARBO | 0 | <14 to >20 | R | |||
| PRADO | 15 | <19 to >24 | R | |||
| ORBI | 0 | <17 to >23 | R | |||
| Tetracyclines | ||||||
| TET | 10 | <18 to >23 | R | tet(K) | Plasmid | |
| DOX | 14 | <20 to >25 | R | |||
| MIN | 18 | <19 to >24 | R | |||
| Macrolide | ||||||
| ERY | 0 | <13 to >23 | R | ermB | Genome | |
| Beta-lactams | ||||||
| OXA | 0 | <16 to >18 | R | mecA, blaZ | Genome | |
| FOX | 30 | <34 to >36 | R | |||
| Lincosamide | ||||||
| CLI | 0 | <14 to >21 | R | ermB | Genome | |
| Phenicols | ||||||
| CHL | 34 | <12 to >18 | S | |||
| FFC | 30 | <12 to >18 | S | |||
| Rifamycin | ||||||
| RIF | 44 | <16 to >20 | S | |||
| Fusidane | ||||||
| FD | 40 | <23 to >25 | S | |||
| SXT | 0 | <10 to >16 | R | dfrG | Genome | |
a
GEN, gentamicin; TOB, tobramycin; AMK, amikacin; CIP, ciprofloxacin; MARBO, marbofloxacin; PRADO, pradofloxacin; ORBI, orbifloxacin; TET, tetracycline; DOX, doxycycline; MIN, minocycline; ERY, erythromycin; OXA, oxacillin; FOX, cefoxitin; CLI, clindamycin; CHL, chloramphenicol; FFC, florfenicol; RIF, rifampin; FD, fusidic acid; SXT, co-trimoxazole.
b
R, resistant; S, sensitive.